Treating desires not diseases: a pill for every ill and an ill for every pill?

  title={Treating desires not diseases: a pill for every ill and an ill for every pill?},
  author={David J. Triggle},
  journal={Drug discovery today},
  volume={12 3-4},
  • D. Triggle
  • Published 1 February 2007
  • Medicine
  • Drug discovery today
Medicines For Body , Love For People : Freirean Lesso ns For Those Who Dare Teach Health Care Professionals
The Freirean perspective won’t be taken as an antidote to the current health care crisis, but an attempt to shed light on important – yet still subjugated – issues related to the ‘rootedness’ of all health care professions in the reality of an ill world.
Exposure to Medicines in the Family Medicine Cabinet: Is It a Harbinger of Later Opioid Dependence?
Findings suggest several adolescent exposures can be targeted to reduce opioid dependence, and parents can reduce their teens’ risk for opioid dependence through their behavior.
The rebirth of psychosocial importance in a drug-filled world.
The reemerging worth of psychotherapeutic relationships in quelling emotional discomfort is highlighted and the roles of business and research bias in overselling the idea of unique merits and specificity of gains derived purely from psychopharmacological solutions are touched on.
Pharmaceuticals in Society
This role of pharmaceuticals in the twenty-first century must be considered not only from a scientific perspective, but also from global social and economic perspectives.
Media, messages, and medication: strategies to reconcile what patients hear, what they want, and what they need from medications
In trying to reconcile patients’ wants and needs for information about prescription medicines, a combination of policy and clinical initiatives may offer greater promise than either approach alone.
Finance and Health
  • P. Banerjee
  • Medicine, Political Science
    India Studies in Business and Economics
  • 2019
The business of health care is currently undergoing a profound transformation. Global finance is forcing transformation of the public policies as well as of the private business of health care. Key
Antidepressant direct-to-consumer prescription drug advertising and public stigma of depression: the mediating role of perceived prevalence of depression
This study examines whether memory of antidepressant direct-to-consumer (DTC) prescription drug advertising is associated with the public stigma attached to depression. Results indicate that those
Effects of Mindfulness Training on Body Awareness to Sexual Stimuli: Implications for Female Sexual Dysfunction
Mindfulness-based improvements in interoceptive awareness highlight the potential of mindfulness training as a treatment of female sexual dysfunction.
A tribute to David Triggle.
  • W. Moos
  • Psychology
    Biochemical pharmacology
  • 2015


Vaccines, Viagra, and Vioxx: medicines, markets, and money—when life‐saving meets life‐style
The key to the continuing expansion of the life‐style drug market is a progressive narrowing of the definition of “normal” coupled with campaigns launched by the pharmaceutical industry that persuade both patients and clinicians that a major and treatable disease does exist and that drug treatment, rather than acceptance of hair loss or occasional lack of sexual interest, is both necessary and appropriate.
Medicines in the 21st century Or pills, politics, potions, and profits: Where is public policy?
The delivery of biomedical science in the future is discussed both in terms of the science that will drive advances and the public policy issues that must be implemented to ensure delivery of scientific benefits.
Manufacturing Desire:
This paper examines how researchers attend professional meetings where they present clinical trial data, lecture at continuing medical education conferences, and offer themselves as ‘experts’ to raise awareness about disorders and their treatments.
Medicine and the Market: Equity v. Choice
Much has been written about medicine and the market in recent years. This book is the first to include an assessment of market influence in both developed and developing countries, and among the very
Pfizer will not apply for a licence for sildenafil for women
  • S. Mayor
  • Psychology, Medicine
    BMJ : British Medical Journal
  • 2004
Pfizer, the company that developed the phosphodiesterase inhibitor sildenafil (Viagra), reported last week that efficacy results in women with what has been termed female sexual arousal disorder had
The ‘Pinking’ of Viagra Culture: Drug Industry Efforts to Create and Repackage Sex Drugs for Women
Key activities and actions that have enabled the drug industry to consolidate power and build capacity in this area are outlined, including: mass dissemination of estimates of disease prevalence; the institutionalization of FSD in academic circles, which includes strategic revision of disease definitions.
Food Marketing to Children and Youth: Threat or Opportunity?
This book will be of interest to parents, federal and state government agencies, educators and schools, health care professionals, industry companies, industry trade groups, media, and those involved in community and consumer advocacy.
COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense.
Within months of rofecoxib’s approval in May 1999, the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial reported a 50% reduction in serious gastrointestinal outcomes, but a 5-fold increase in thromboembolic cardiovascular events (primarily acute myocardial infarction [MI]) among patients treated with 50 mg/d of roFECoxib compared with 1000 mg/D of naproxen.
Conflicts between Commercial and Scientific Interests in Pharmaceutical Advertising for Medical Journals
  • A. Tsai
  • Medicine
    International journal of health services : planning, administration, evaluation
  • 2003
A detailed account of third-party reactions to the study following its publication in the Annals of Internal Medicine is provided, as well as the implications for those involved, including the authors, editors, and publisher.
National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.
There has been a sharp national increase in antipsychotic treatment among children and adolescents in office-based medical practice, and emerging empirical evidence provides a base of support that is limited to short-term safety and efficacy.